Cobra Embarks on £15m Manufacturing Operations Expansion

Cobra Biologics is to expand its manufacturing sites in both Sweden and the UK to meet increased demand from clients wishing to fast track portfolios through to in-market supply.

Over the next two years the CDMO will invest up to £15m (165m SEK), supporting its R&D expertise in developing rapid and cost effective viral vector and DNA plasmid production platforms. The initial phase in the UK will extend the company’s viral vector Phase III and commercial manufacturing capabilities to support more customers through clinical trials to in-market supply. The second phase, in Sweden, will double capacity for High Quality (HQ) DNA plasmid production and characterisation, essential for supporting early clinical phase Adeno-associated virus (AAV) and lentivirus manufacture being used by pioneering CAR T-cell therapy companies targeting acute lymphoblastic leukaemia (ALL) and chronic lymphocytic leukaemia.

The third phase of investment will see the addition of larger clinical and commercial capabilities for GMP DNA production. In total, it is anticipated these investments will create up to 50 new jobs, in addition to the 135 jobs already created in the UK and Sweden since 2011 and will also benefit the wider supply chain companies which provide Cobra with services and facilities.

Peter Coleman, CEO at Cobra Biologics, said: “For almost 20 years Cobra has been manufacturing DNA and viral vectors for its gene therapy customers and we intend to stay at the forefront of this exciting field. Cobra is committed to investing for both present day needs and for the future at this extraordinary time in the history of gene therapy when so many new and potentially life-changing medicines are in the pipe line. Many of these new pro products have orphan drug status and as a CDMO, we need to respond with a quick and seamless production route to market.”